How Jeffrey Epstein's friend came back to biotech, probes into the FDA's drug rejections, and other biotech news ...

You can read more about Chou’s new nonprofit venture, Radial, in my colleague Allison DeAngelis’ exclusive new story, ...

The first patient I met as a medical student was a middle-aged delivery man and a former track athlete. He was recovering from his second amputation due to uncontrolled type 2 diabetes. When he told ...

The FDA approves leucovorin for a rare brain disorder while retreating from top officials’ earlier insistence that it could ...

AI agents to perform health care work are everywhere at HIMSS 2026. Experts want to know more about their validation.

The Trump administration push for lower U.S. drug prices helped Astellas secure higher pricing for its new eye medicine in Japan ...

A new nonprofit called Radial is launching with at least $500 million to modernize the scientific process for the AI era.

Epstein's "great friend" returns to biotech, sex differences in suicide, and other health news from Morning Rounds ...

Boris Nikolic’s career looked to be in tatters after his friendship with Jeffrey Epstein came to light in 2019. But he has quietly made a comeback, with some help from a top biotech VC.

Removing race from the eGFR had a big impact, resulting in 5.3 more kidney transplants per 1000 Black candidates.

In the breakup between Dana-Farber Cancer Institute and Mass General Brigham, the sides have decided to go with conscious uncoupling rather than an acrimonious divorce.

The co-founders of the Covid-19 vaccine developer BioNTech plan to leave the biotech to start a new mRNA-focused company ...